Three Cell And Gene Therapies Reach Critical Review Stage In EU

BMS, bluebird bio And PTC Therapeutics Need To Address Reviewers' Outstanding Issues

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".